Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (formerly traded on Nasdaq under the symbol SCPH) generated a steady stream of company-specific news before and during its acquisition by MannKind Corporation. Public announcements and SEC filings show that scPharmaceuticals focused on cardiorenal healthcare, with news often centered on FUROSCIX, a subcutaneous furosemide injection indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
News coverage for scPharmaceuticals has included product and clinical updates, such as FDA approval of an expanded FUROSCIX indication to include chronic kidney disease and the formal launch of FUROSCIX into that market. The company also reported progress on its SCP-111 furosemide formulation and related autoinjector program, including multiple Notices of Allowance from the U.S. Patent and Trademark Office for patents covering SCP-111 and plans for supplemental NDA submissions.
Financial and corporate updates have been another major theme. scPharmaceuticals regularly issued press releases on quarterly and annual financial results, highlighting net FUROSCIX revenues, dose volumes, prescriber adoption, and expansion into integrated delivery networks. Additional news detailed participation in investor conferences, financing arrangements, and credit facilities.
A key set of news items in 2025 described MannKind’s agreement to acquire scPharmaceuticals, the tender offer terms, and the strategic rationale around cardiorenal and cardiometabolic care. Subsequent releases and a Form 8-K dated October 7, 2025 confirmed completion of the tender offer and merger, after which scPharmaceuticals became a wholly owned subsidiary of MannKind and its shares were delisted from Nasdaq. This news page therefore serves as an archive of historical announcements, from product and regulatory milestones to the transaction that ended SCPH’s life as an independent public stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
scPharmaceuticals Inc. (SCPH) has launched FUROSCIX®, the first self-administered subcutaneous loop diuretic for chronic heart failure treatment, effective February 20, 2023. The company ended Q4 2022 with $118.4 million in cash and reported a net loss of $9.2 million for the quarter. This represents an increase from $7.3 million in Q4 2021. The company also completed a $50 million stock offering and a $100 million secured debt financing to support FUROSCIX commercialization. Expectations indicate rising operational costs in 2023 for marketing efforts. CEO John Tucker expressed optimism regarding FUROSCIX's potential impact on patient care.